Business Context and Reporting Period
This Form 8-K Current Report was filed by MedaSorb Technologies Corporation (referred to in metadata as Cytosorbents Corp) on July 23, 2008. The report details changes to the Company's Board of Directors and Compensation Committee effective July 23 and July 24, 2008.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics. However, it references a recent financing event: on June 25, 2008, the Company completed a $4.275 million private placement of Series B 10% Cumulative Convertible Preferred Stock.
- Total Placement: $4.275 million
- NJTC Venture Fund SBIC, L.P. Investment: $2.0 million (20,000 shares)
- Dr. Chan Investment: $10,000
Material Changes
The primary material change reported is the restructuring of the Board of Directors:
- Resignation: Kurt Katz resigned as a member of the Board of Directors effective July 23, 2008.
- Appointments: James Gunton and Phillip Chan were appointed to the Board of Directors and Compensation Committee effective July 24, 2008.
- Rationale: These appointments were made as nominees of NJTC Venture Fund SBIC, L.P. pursuant to the Certificate of Designation for the Series B Preferred Stock, which grants NJTC the right to elect two directors and two compensation committee members while holding 25% of the Series B shares purchased at the Initial Closing.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The document is strictly a disclosure of corporate governance changes resulting from the terms of the recent Series B Preferred Stock issuance.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and Compensation Committee following the July 2008 changes.
- Confirm the ownership percentage of NJTC Venture Fund SBIC, L.P. in the Series B Preferred Stock to ensure their continued right to appoint directors.
- Review the terms of the Series B 10% Cumulative Convertible Preferred Stock regarding dividend obligations and conversion rights.
- Check subsequent filings for any further changes in executive leadership or board composition.